EYPT — Eyepoint Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $437.80m
- $66.89m
- $43.27m
- 33
- 18
- 15
- 10
Annual cashflow statement for Eyepoint Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -45.4 | -58.4 | -102 | -70.8 | -131 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 8.17 | 7.29 | 37.8 | 13.2 | 30.8 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 20.1 | -1.74 | -3.02 | 59 | -27.8 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -14.4 | -50.1 | -65 | 1.88 | -126 |
| Capital Expenditures | -0.362 | -0.156 | -2.15 | -3.48 | -4.05 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -33 | -15.1 | 0.168 | -215 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.362 | -33.1 | -17.3 | -3.31 | -219 |
| Financing Cash Flow Items | -0.918 | -0.15 | -3.19 | -1.97 | -5.18 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 37.5 | 217 | -0.69 | 187 | 164 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 22.7 | 134 | -83 | 186 | -182 |